<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03681808</url>
  </required_header>
  <id_info>
    <org_study_id>885</org_study_id>
    <nct_id>NCT03681808</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Effectiveness of the Biotrue ONEday for Astigmatism</brief_title>
  <official_title>A Study to Evaluate the Safety and Effectiveness of the Biotrue ONEday for Astigmatism Soft Contact Lens When Worn on a Daily Basis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing Test Lens for Astigmatism Soft Contact Lens (Test) to 1-Day Control for Astigmatism
      contact lenses (Control).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized 1:1, parallel-group, bilateral, Investigator-masked study
      at 13 investigative sites in the United States (US) in a population including Chinese
      subjects (maternal and paternal grandparents born in China)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2018</start_date>
  <completion_date type="Actual">December 16, 2019</completion_date>
  <primary_completion_date type="Actual">December 16, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Investigator/Sponsor masked, randomized, open-label, parallel-group, multicenter study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Subjects will be dispensed product according to the treatment arm corresponding to their randomization and will be unmasked. The Investigator will be masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Corrected Distance</measure>
    <time_frame>Evaluated at the 1 week follow up visit</time_frame>
    <description>the proportion of subjects achieving a contact lens corrected distance logMAR VA of 0.04 or better in both eyes</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">246</enrollment>
  <condition>Astigmatism</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Soft Contact Lens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Contact lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Contact Lens</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Test</intervention_name>
    <description>Soft Contact Lens</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be of legal age (at least 18 or as defined by state law) on the date the
             ICF is signed and have the capacity to provide voluntary informed consent.

          -  Subject must be able to read, understand and provide written informed consent on the
             IRB approved ICF and provide authorization as appropriate for local privacy
             regulations.

          -  Subject must have physiologically normal anterior segments not exhibiting clinically
             significant biomicroscopy findings (greater than Grade 1 and/or presence of
             infiltrates) and have clear central 6 mm corneas.

          -  Subject must be an adapted wearer of soft contact lenses, wear a lens in each eye, and
             each lens must be of the same manufacture and brand.

        Exclusion Criteria:

          -  Subject has worn gas permeable (GP) contact lenses within last 30 days or
             polymethylmethacrylate (PMMA) lenses within last 3 months.

          -  Subject has systemic disease affecting ocular health.

          -  Subject is using any systemic or topical medications that will affect ocular
             physiology or lens performance.

          -  Subject has an active ocular disease (for example but not limited to papillary
             conjunctivitis, any conjunctivitis: viral, bacterial, allergic), any corneal
             infiltrative response or are using any ocular medications.

          -  Subject has any &quot;Present&quot; finding during the slit lamp examination that, in the
             Investigator's judgment, interferes with contact lens wear
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsey Mathew</last_name>
    <role>Study Director</role>
    <affiliation>Bausch Health Companies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch Site 117</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 107</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 101</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 108</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 104</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94087</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 102</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 116</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 110</name>
      <address>
        <city>Brighton</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 118</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 111</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 114</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 105</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Site 115</name>
      <address>
        <city>Issaquah</city>
        <state>Washington</state>
        <zip>98027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2018</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

